IceCure Medical FY2026 EPS Estimate Cut by Brookline Cap M

IceCure Medical Ltd. (NASDAQ:ICCM) – Research analysts at Brookline Cap M cut their FY2026 EPS estimates for IceCure Medical in a research note issued on Tuesday, March 17th. Brookline Cap M analyst K. Dolliver now anticipates that the company will post earnings of ($0.12) per share for the year, down from their previous forecast of ($0.06). The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Cap M also issued estimates for IceCure Medical’s FY2027 earnings at ($0.09) EPS, FY2028 earnings at ($0.04) EPS and FY2029 earnings at $0.08 EPS.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 221.04%. The business had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.30 million.

ICCM has been the topic of several other reports. Wall Street Zen raised IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, IceCure Medical currently has an average rating of “Hold” and a consensus target price of $2.64.

IceCure Medical Stock Performance

IceCure Medical stock opened at $0.63 on Friday. IceCure Medical has a 52 week low of $0.54 and a 52 week high of $1.40. The stock has a market capitalization of $45.95 million, a P/E ratio of -2.62 and a beta of 0.29. The stock has a fifty day moving average of $0.62 and a 200-day moving average of $0.74.

Institutional Investors Weigh In On IceCure Medical

A number of institutional investors have recently added to or reduced their stakes in ICCM. Virtu Financial LLC acquired a new position in IceCure Medical in the 4th quarter valued at approximately $39,000. Concurrent Investment Advisors LLC bought a new position in shares of IceCure Medical during the fourth quarter valued at $48,000. Finally, Jane Street Group LLC acquired a new position in shares of IceCure Medical during the fourth quarter worth $67,000. 0.62% of the stock is owned by institutional investors.

IceCure Medical News Roundup

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: New peer‑reviewed PLOS One data highlighted by the company show its ProSense cryoablation is effective for treating breast fibroadenomas — a clinical win that supports product utility and potential commercial adoption if follow‑on studies/commercialization progress. IceCure Medical Highlights New PLOS One Data Showing ProSense Cryoablation Effective for Breast Fibroadenomas
• Positive Sentiment: Brookline Cap M’s long‑range model includes positive multi‑year estimates (FY2029/FY2030 projections) that suggest some analysts see upside over the longer term despite near‑term weakness — this can act as a tailwind if execution and commercial uptake match assumptions. ICCM on MarketBeat
• Neutral Sentiment: Q4 2025 earnings call transcript is available for review — useful for investors wanting management commentary on sales, clinical programs and cash burn after the recent quarterly miss. That context may influence positioning but is informational rather than a new catalyst. IceCure Medical Ltd (NASDAQ:ICCM) Q4 2025 earnings call transcript
• Negative Sentiment: Brookline Cap M issued a series of downward revisions to near‑term EPS estimates (cuts to FY2026, FY2027 and FY2028 and lowered quarterly 2026 EPS projections). Those model cuts lower near‑term profitability expectations and are the primary negative driver weighing on the stock today. ICCM on MarketBeat
• Negative Sentiment: Recent fundamental metrics (recent quarterly EPS miss, negative margins and high negative ROE) combined with the analyst downgrades increase downside risk until management can show consistent revenue growth or margin improvement. Investors should expect continued volatility around execution updates and clinical/commercial milestones. ICCM on MarketBeat

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.